• Explore /
  • Poster
  • / Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

Randomized phase II study of 2nd line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

Abstract Poster

Authors

E. Gabriela Chiorean

E. Gabriela Chiorean

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA

E. Gabriela Chiorean , Katherine A Guthrie , Philip Agop Philip , Elizabeth M. Swisher , Florencia Jalikis , Michael J. Pishvaian , Jordan Berlin , Marcus Smith Noel , Jennifer Marie Suga , Ignacio Garrido-Laguna , Dana Backlund Cardin , Danika L. Lew , Andrew M. Lowy , Howard S. Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT02890355

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4014)

DOI

10.1200/JCO.2019.37.15_suppl.4014

Abstract #

4014

Poster Bd #

119

Abstract Disclosures

Similar Posters

First Author: Elias Chandran

First Author: Anup Kasi

First Author: Thomas J. George

First Author: Amy E. Chang